Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16422Full metadata record
| ???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
|---|---|---|
| dc.contributor.advisor | 楊台鴻 | |
| dc.contributor.author | Ru-Wen Chang | en |
| dc.contributor.author | 張如文 | zh_TW |
| dc.date.accessioned | 2021-06-07T18:14:12Z | - |
| dc.date.copyright | 2012-06-29 | |
| dc.date.issued | 2012 | |
| dc.date.submitted | 2012-06-04 | |
| dc.identifier.citation | Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C et al. (1980). Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A 1980;77(7):3957-61
American Diabetes Association (2006). Diagnosis and classification of diabetes mellitus. Diabetes Care 2006;29(Suppl 1):S43-8. Amos AF, McCarty DJ, Zimmet P (1997). The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14(Suppl 5):S1-85 Bach JF (1994). Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994;15(4):516-42. Bardell AL, MacLeod KM (2001). Evidence for inducible nitric-oxide synthase expression and activity in vascular smooth muscle of streptozotocin-diabetic rats. J Pharmacol Exp Ther 2001;296(2):252-9. Bardou M, Barkun A, Martel M (2010). Effect of statin therapy on colorectal cancer. Gut 2010;59(11):1572-85 Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM et al. (2007). HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357(13):1301-10. Betteridge DJ (2011). Lipid control in patients with diabetes mellitus. Nat Rev Cardiol 2011;8(5):278-90. Blaha V, Zadak Z, Solichova D, Bratova M, Havel E (1998). Hypocholesterolemic effect of pravastatin is associated with increased content of antioxidant vitamin-E in cholesterol fractions. Acta Medica (Hradec Kralove) 1998;41(2):87-90. Boden WE (2000). High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. Am J Cardiol 2000;86(12A):19L-22L. Borniquel S, Valle I, Cadenas S, Lamas S, Monsalve M (2006). Nitric oxide regulates mitochondrial oxidative stress protection via the transcriptional coactivator PGC-1alpha. FASEB J 2006;20(11):1889-91. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S et al. (2007). PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007;6(2):137-43. Broedbaek K, Weimann A, Stovgaard ES, Poulsen HE (2011). Urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine as a biomarker in type 2 diabetes. Free Radic Biol Med 2011;51(8):1473-9. Brown JH, Del Re DP, Sussman MA (2006). The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 2006;98(6):730-42. Brown MS, Goldstein JL (1997). The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997;89(3):331-40. Brownlee M (2005). The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54(6):1615-25. Burattini R, Fioretti S, Jetto L (1985). A simple algorithm for defining the mean cardiac cycle of aortic flow and pressure during steady state. Comput Biomed Res 1985;18(4):303-12. Burg JS, Espenshade PJ (2011). Regulation of HMG-CoA reductase in mammals and yeast. Prog Lipid Res 2011;50(4):403-10. Caballero AE (2003). Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003;11(11):1278-89. Chang KC, Chen TJ, Peng YI, Li TH, Tseng YZ (2000). Impaired vascular dynamics in normotensive diabetic rats induced by streptozotocin: tapered T-tube model analysis. J Theor Biol 2000;204(3):371-80. Chang KC, Hsu KL, Tseng CD, Lin YD, Cho YL, Tseng YZ (2006). Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats. Br J Pharmacol 2006;147(8):944-50. Chang KC, Hsu KL, Tseng YZ (2003). Effects of diabetes and gender on mechanical properties of the arterial system in rats: aortic impedance analysis. Exp Biol Med 2003;228(1):70-8. Chang KC, Liang JT, Tsai PS, Wu MS, Hsu KL (2009). Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen. Br J Pharmacol 2009;157(8):1419-26. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK (1993). Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 1993;94(1):109-10. Charlton-Menys V, Durrington PN (2008). Human cholesterol metabolism and therapeutic molecules. Exp Physiol 2008;93(1):27-42. Christians U, Jacobsen W, Floren LC (1998). Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998;80(1):1-34. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM (1994). Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 1994;267(5 Pt 1):C1405-13. De Caterina R (2000). Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Lipidol 2000;11(1):9-23. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr et al. (1995). Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96(1):60-8. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM (1999). Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399(6736):601-5. Dimmeler S, Zeiher AM (1999). Nitric oxide-an endothelial cell survival factor. Cell Death Differ 1999;6(10):964-8. Draper HH, Hadley M (1990). Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 1990;186:421-31. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. (2009). Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360(2):129-39. Duffy D, Rader DJ (2009). Update on strategies to increase HDL quantity and function. Nat Rev Cardiol 2009;6(7):455-63. Dusting GJ, Selemidis S, Jiang F (2005). Mechanisms for suppressing NADPH oxidase in the vascular wall. Mem Inst Oswaldo Cruz 2005;100 Suppl 1:97-103. Endemann DH, Schiffrin EL (2004). Endothelial dysfunction. J Am Soc Nephrol 2004;15(8):1983-92. Endo A, Kuroda M, Tsujita Y (1976). ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo) 1976;29(12):1346-8. Endres M (2005). Statins and stroke. J Cereb Blood Flow Metab 2005;25(9):1093-110. Evans M, Rees A (2002). Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002;25(9):649-63. Evans RM, Barish GD, Wang YX (2004). PPARs and the complex journey to obesity. Nat Med 2004;10(4):355-61. Ewing DJ, Campbell IW, Clarke BF (1980). Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications. Ann Intern Med 1980;92(2 Pt 2):308-11. Feron O, Dessy C, Desager JP, Balligand JL (2001). Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001;103(1):113-8. Finkel T, Holbrook NJ (2000). Oxidants, oxidative stress and the biology of ageing. Nature 2000;408(6809):239-47. Fleming I, Busse R (1999). NO: the primary EDRF. J Mol Cell Cardiol 1999;31(1):5-14. Forman BM, Ruan B, Chen J, Schroepfer GJ Jr, Evans RM (1997). The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci U S A 1997;94(20):10588-93. Fujii M, Takemura R, Yamaguchi M, Hasegawa G, Shigeta H, Nakano K et al. (1997). Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Metabolism 1997;46(9):981-3. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K et al. (1999). Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999;399(6736):597-601. Ganguly PK, Pierce GN, Dhalla KS, Dhalla NS (1983). Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am J Physiol 1983;244(6):E528-35. Ginsberg HN, Huang LS (2000). The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 2000;7(5):325-31. Glomset JA (1968). The plasma lecithins: cholesterol acyltransferase reaction. J Lipid Res 1968;9(2):155-67. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP et al. (1999). Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34(6):1281-6. Goldstein BJ (2003). Insulin resistance: from benign to type 2 diabetes mellitus. Rev Cardiovasc Med 2003;4(Supple 6):S3-10. Grundy SM (1978). Cholesterol metabolism in man. West J Med 1978;128(1):13-25. Guyton AC (1992). Human Physiology and Mechanisms of Disease. Philadelphia: Saunders, 1992. Harrison DG (1997). Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997;100(9):2153-7. Hattori Y, Nakanishi N, Akimoto K, Yoshida M, Kasai K (2003). HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2003;23(2):176-82. Havel PJ, Uriu-Hare JY, Liu T, Stanhope KL, Stern JS, Keen CL et al. (1998). Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin. Am J Physiol 1998;274(5 Pt 2):R1482-91. Herman MA, Kahn BB (2006). Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J Clin Invest 2006;116(7):1767-75. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M et al. (2001). Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001;88:E14-E22. Ilstrup KM, Keane WF, Michels LD (1981). Intravascular and extracellular volumes in the diabetic rat. Life Sci 1981;29(7):717-24. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K et al. (1990). Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323(18):1234-8. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M et al. (2000). High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000;49(11):1939-45. Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N et al. (2003). Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003;14(8 Suppl 3):S227-32. Istvan ES, Deisenhofer J (2001). Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292(5519):1160-4. Jones P, Kafonek S, Laurora I, Hunninghake D (1998). Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81(5):582-7. Junod A, Lambert AE, Stauffacher W, Renold AE (1969). Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J Clin Invest 1969;48(11):2129-39. Kawahito S, Kitahata H, Oshita S (2009). Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol 2009;15(33):4137-42. Kawashima S (2004). The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis. Endothelium 2004;11(2):99-107. Khan AH, Pessin JE (2002). Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia 2002;45(11):1475-83. Knopp RH (1999). Drug treatment of lipid disorders. N Engl J Med 1999;341(7):498-511. Kobayashi T (1994). Subtype of insulin-dependent diabetes mellitus (IDDM) in Japan: slowly progressive IDDM--the clinical characteristics and pathogenesis of the syndrome. Diabetes Res Clin Pract 1994;24 Suppl:S95-9. Krieger M, Herz J (1994). Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 1994;63:601-37. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ et al. (2000). The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6(9):1004-10. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M et al. (2002). Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002;55(1):65-85. Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ et al. (1996). The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996;77(10):851-4. Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V et al. (2007). Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem 2007;14(2):243-8. Landrier JF, Thomas C, Grober J, Duez H, Percevault F, Souidi M et al. (2004). Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent. J Biol Chem 2004;279(44):45512-8. Laufs U (2003). Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 2003;58(11):719-31. Laufs U, Fata VL, Liao JK (1997). Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997;272(50):31725-9. Laufs U, Liao JK (1998). Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273(37):24266-71. Laufs U, Liao JK (2000). Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2000;10(4):143-8. Laufs U, Liao JK (2000). Targeting Rho in cardiovascular disease. Circ Res 2000;87(7):526-8. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA et al. (2001). Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001;103(9):1282-8. Laxminarayan S, Sipkema P, Westerhof N (1978). Characterization of the arterial system in the time domain. IEEE Trans Biomed Eng 1978;25(2):177-84. Lefer AM, Scalia R, Lefer DJ (2001). Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001;49(2):281-7. Liao JK (1998). Endothelium and acute coronary syndromes. Clin Chem 1998;44(8 Pt 2):1799-808. Libby P (2000). Inflammation in atherosclerosis. Nature 2002;420(6917):868-74. Libby P, Ridker PM, Hansson GK (2011). Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473(7347):317-25. Liu Z, Brin KP, Yin FC (1986). Estimation of total arterial compliance: an improved method and evaluation of current methods. Am J Physiol 1986;251(3 Pt 2):H588-600. Lykkesfeldt J (2007). Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. Clin Chim Acta 2007;380(1-2):50-8. Machlin LJ, Bendich A (1987). Free radical tissue damage: protective role of antioxidant nutrients. FASEB J 1987;1(6):441-5. Madamanchi NR, Vendrov A, Runge MS (2005). Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005;25(1):29-38. Matsuki A, Nozawa T, Igarashi N, Sobajima M, Ohori T, Suzuki T et al. (2010). Fluvastatin attenuates diabetes-induced cardiac sympathetic neuropathy in association with a decrease in oxidative stress. Circ J 2010;74(3):468-75. McDonald DA (1974). Blood Flow in Arteries. London: Arnold, 1974. McFarlane SI, Muniyappa R, Francisco R, Sowers JR (2002). Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002;87(4):1451-8. Meiner V, Tam C, Gunn MD, Dong LM, Weisgraber KH, Novak S et al. (1997). Tissue expression studies on the mouse acyl-CoA: cholesterol acyltransferase gene (Acact): findings supporting the existence of multiple cholesterol esterification enzymes in mice. J Lipid Res 1997;38(9):1928-33. Milnor WR (1975). Arterial impedance as ventricular afterload. Circ Res 1975;36(5):565-70. Milnor WR (1989). Hemodynamics. Baltimore: Williams & Wilkins, 1989. Milstien S, Katusic Z (1999). Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 1999;263(3):681-4. Miserez AR, Rossi FA, Keller U (1994). Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects. Eur J Clin Pharmacol 1994;46(2):107-14. Mitchell GF, Pfeffer MA, Westerhof N, Pfeffer JM (1994). Measurement of aortic input impedance in rats. Am J Physiol 1994;267(5 Pt 2):H1907-15. Moncada S, Higgs EA (1995). Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 1995;9(13):1319-30. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM (2011). HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011;8(4):222-32. Nichols WW, Conti CR, Walker WE, Milnor WR (1977). Input impedance of the systemic circulation in man. Circ Res 1977;40(5):451-8. Nichols WW, O'Rourke MF (1998). McDonald's Blood Flow in Arteries. London: Arnold, 1998. Nichols WW, O'Rourke MF (2005). McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles, 2005. Nichols WW, Pepine CJ, Geiser EA, Conti CR (1980). Vascular load defined by the aortic input impedance spectrum. Fed Proc 1980;39(2):196-201. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y et al. (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404(6779):787-90. Noble MI, Gabe IT, Trenchard D, Guz A (1967). Blood pressure and flow in the ascending aorta of conscious dogs. Cardiovasc Res 1967;1(1):9-20. Nolan CR (2005). Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines. Kidney Int Suppl 2005;(96):S7-14. Packard CJ (2003). Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003;31(Pt 5):1066-9. Pahl HL (1999). Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18(49):6853-66. Palinski W, Tsimikas S (2002). Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 2002;13(6):1673-81. Pandolfi A, De Filippis EA (2007). Chronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications. Genes Nutr 2007;2(2):195-208. Pasceri V, Willerson JT, Yeh ET (2000). Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102(18):2165-8. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C et al. (2002). ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40(3):567-72. Patel KP, Zhang PL (1989). Reduced renal responses to volume expansion in streptozotocin-induced diabetic rats. Am J Physiol 1989;257(3 Pt 2):R672-9. Peng HB, Libby P, Liao JK (1995). Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 1995;270(23):14214-9. Peng YI, Chang KC (2000). Acute effects of methoxamine on left ventricular-arterial coupling in streptozotocin-diabetic rats: a pressure-volume analysis. Can J Physiol Pharmacol 2000;78(5):415-22. Penpargkul S, Fein F, Sonnenblick EH, Scheuer J (1981). Depressed cardiac sarcoplasmic reticular function from diabetic rats. J Mol Cell Cardiol 1981;13(3):303-9. Pepine CJ, Nichols WW (1982). Aortic input impedance in cardiovascular disease. Prog Cardiovasc Dis 1982;24(4):307-18. Pfeffer MA, Sacks FM, Moye LA, East C, Goldman S, Nash DT et al. (1999). Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events. J Am Coll Cardiol 1999;33(1):125-30. Pieper GM, Moore-Hilton G, Roza AM (1996). Evaluation of the mechanism of endothelial dysfunction in the genetically-diabetic BB rat. Life Sci 1996;58(9):PL147-52. Rakieten N, Rakieten ML, Nadkarni MR (1963). Studies on the diabetogenic action of streptozotocin. Cancer Chemother Rep 1963;29:91-8. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL (2008). Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51(4):415-26. Rao GN, Berk BC (1992). Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 1992;70(3):593-9. Riad A, Du J, Stiehl S, Westermann D, Mohr Z, Sobirey M et al. (2007). Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus. Eur J Pharmacol 2007;569(3):204-11. Righetti M, Wiley MH, Murrill PA, Siperstein MD (1976). The in vitro metabolism of mevalonate by sterol and non-sterol pathways. J Biol Chem 1976;251(9):2716-21. Rikitake Y, Liao JK (2005). Rho GTPases, statins, and nitric oxide. Circ Res 2005;97(12):1232-5. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N et al. (2000). Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000;80(7):1095-100. Ross J, Covell J, Sonnenblick E, Braunwald E (1966). Contractile State of the Heart Characterized by Force-Velocity Relations in Variably Afterloaded and Isovolumic Beats. Circulation Research 1966;18:149-63. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ et al. (2007). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28(1):88-136. Sabri A, Hughie HH, Lucchesi PA (2003). Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid Redox Signal 2003;5(6):731-40. Saltiel AR, Kahn CR (2001). Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414(6865):799-806. Savarese JJ, Berkowitz BA (1979). β-Adrenergic receptor decrease in diabetic rat hearts. Life Sci 1979;25(24-25):2075-8. Schachinger V, Zeiher AM (2002). Atherogenesis--recent insights into basic mechanisms and their clinical impact. Nephrol Dial Transplant 2002;17(12):2055-64. Schalkwijk CG, Stehouwer CD (2005). Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 2005;109(2):143-59. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20):1301-7. Shepherd PR, Kahn BB (1999). Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. N Engl J Med 1999;341(4):248-57. Sies H (1997). Oxidative stress: oxidants and antioxidants. Exp physiol 1997;82(2):291-5. Sipkema P, Westerhof N, Randall OS (1980). The arterial system characterised in the time domain. Cardiovasc Res 1980;14(5):270-9. Slatter DA, Bolton CH, Bailey AJ (2000). The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia 2000;43(5):550-7. Slatter DA, Paul RG, Murray M, Bailey AJ (1999). Reactions of lipid-derived malondialdehyde with collagen. J Biol Chem 1999;274(28):19661-9. Smith JM, Paulson DJ, Romano FD (1997). Inhibition of nitric oxide synthase by L-NAME improves ventricular performance in streptozotocin-diabetic rats. J Mol Cell Cardiol 1997;29(9):2393-402. Sposito AC, Chapman MJ (2002). Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002;22(10):1524-34. Springer TA (1994). Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76(2):301-14. Stadler K, Jenei V, Somogyi A, Jakus J (2005). Beneficial effects of aminoguanidine on the cardiovascular system of diabetic rats. Diabetes Metab Res Rev 2005;21(2):189-96. Stalker TJ, Lefer AM, Scalia R (2001). A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol 2001;133(3):406-12. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW (1997). Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997;34(1):55-68. Stein EA, Lane M, Laskarzewski P (1998). Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81(4A):66B-69B. Steinberg D (2009). The LDL modification hypothesis of atherogenesis: an update. J Lipid Res 2009;50 Suppl:S376-81. Steinberger J, Daniels SR (2003). Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 2003;107(10):1448-53. Stumvoll M, Goldstein BJ, van Haeften TW (2005). Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365(9467):1333-46. Suzumura K, Kasahara E, Ohnishi Y, Chien KC, Inoue M (2000). Fluvastatin normalizes the decreased turnovers of glutathione and ascorbic acid in Watanabe heritable hyperlipidaemic rabbits. Clin Exp Pharmacol Physiol 2000;27(9):709-14. Tabas I, Williams KJ, Boren J (2007). Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007 ;116(16):1832-44. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y et al. (2001). Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001;108(10):1429-37. Tomlinson KC, Gardiner SM, Bennett T (1989). Diabetes mellitus in Brattleboro rats: cardiovascular, fluid, and electrolyte status. Am J Physiol 1989;256(6 Pt 2):R1279-85. Tomlinson KC, Gardiner SM, Hebden RA, Bennett T (1992). Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol Rev 1992;44(1):103-50. Tsao PS, Wang B, Buitrago R, Shyy JY, Cooke JP (1997). Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997;96(3):934-40. Tsubouchi H, Inoguchi T, Sonta T, Sato N, Sekiguchi N, Kobayashi K et al. (2005). Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radic Biol Med 2005;39(4):444-52. Ucar M, Mjorndal T, Dahlqvist R (2000). HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000;22(6):441-57. Urso ML, Clarkson PM (2003). Oxidative stress, exercise, and antioxidant supplementation. Toxicology 2003;189(1-2):41-54. Usui H, Shikata K, Matsuda M, Okada S, Ogawa D, Yamashita T et al. (2003). HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 2003;18(2):265-72. Vallance P, Collier J, Moncada S (1989). Nitric oxide synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivo. Cardiovasc Res 1989;23(12):1053-7. Van Linthout S, Riad A, Dhayat N, Spillmann F, Du J, Dhayat S et al. (2007). Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia 2007;50(9):1977-86. Vara JJ, Deboer C, Dietz A, Hanka LJ, Sokolski WT (1959). Streptozotocin, a new antibacterial antibiotic. Antibiot Annu 1959-1960;7:230-5. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H et al. (1998). Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 1998;95(16):9220-5. Violi F, Marino R, Milite MT, Loffredo L (1999). Nitric oxide and its role in lipid peroxidation. Diabetes Metab Res Rev 1999;15(4):283-8. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M (2000). Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20(1):61-9. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT et al. (2002). Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002;22(2):300-5. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA et al. (2004). Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004;113(10):1408-18. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C et al. (2001). Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7(6):687-92. Wenzel P, Daiber A, Oelze M, Brandt M, Closs E, Xu J et al. (2008). Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis 2008;198(1):65-76. West of Scotland Coronary Prevention Study Group (1998). Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97(15):1440-5. Westerhof N, Sipkema P, van den Bos GC, Elzinga G (1972). Forward and backward waves in the arterial system. Cardiovasc Res 1972;6(6):648-56. Williams HC, Griendling KK (2007). NADPH oxidase inhibitors: new antihypertensive agents? J Cardiovasc Pharmacol 2007;50(1):9-16. Williamson JR, Chang K, Tilton RG, Kilo C (1989). Models for studying diabetic complications. In: Diabetes Mellitus: Pathophysiology and Therapy. eds. Creutzfeldt W & Lefebvre P, pp. 142-151. NewYork: Springer-Verlag. Yan ZQ, Yokota T, Zhang W, Hansson GK (1996). Expression of inducible nitric oxide synthase inhibits platelet adhesion and restores blood flow in the injured artery. Circ Res 1996;79(1):38-44. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R (1995). Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 1995;76(6):980-6. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16422 | - |
| dc.description.abstract | 研究背景與目的：高血糖與血脂異常為糖尿病患者共有的特徵，這不僅會增加患者體內的氧化壓力，亦會降低一氧化氮之生物可利用率，因而造成內皮細胞功能異常。目前已證實，內皮細胞功能異常在糖尿病患者形成心血管疾病的病理過程中，佔有重要的影響力。Statins是3-羥基-3-甲基戊二醯輔酶A (3-hydroxyl-3-methylglutaryl coenzyme A, HMG-CoA) 還原酶的抑制劑，能夠有效降低血中脂質，故常用來作為預防心血管疾病的用藥；此外，statins也可以透過非膽固醇途徑或稱為多效作用，降低心血管事件發生的機率。文獻指出，使用低劑量的atorvastatin (Ator) 可在不改變脂質含量的情況下，造成氧化壓力的降低。本實驗以此為基礎，在不影響總膽固醇含量且能夠降低氧化壓力的狀態下，評估低劑量Ator對streptozotocin (STZ) 所誘發糖尿病鼠之動脈系統物理性質的影響。
研究方法：雄性Wistar 大白鼠於兩個月大時，以尾靜脈注射每公斤55毫克（55 mg kg-1）的STZ以誘發糖尿病的產生。待大鼠出現高血糖症狀後，給予餵食組每日灌食每公斤10毫克（10 mg kg-1）的Ator，連續給藥六週，並與同齡未給藥之糖尿病控制組作對照。在升主動脈處，使用高傳真Millar導管與電磁血流探頭分別測得脈態血壓與血流訊號，經主動脈輸入阻抗頻譜分析以探討動脈系統的物理性質與脈波的反射現象。每隻動物在取得所需訊號之後，隨即犧牲動物以採集血液與組織樣本，進行游離脂肪酸、總膽固醇以及丙二醛/硫代巴比妥酸反應物質的分析。 結果：本實驗觀察到低劑量的Ator能夠顯著降低糖尿病鼠血漿中游離脂肪酸與丙二醛含量，但不會對總膽固醇造成影響。與糖尿病控制組相較，餵食Ator的糖尿病鼠在主動脈血壓參數、基礎心跳速率、心輸出量以及周邊總阻力皆無顯著差異。然而，Ator會增加糖尿病鼠之主動脈特徵阻抗，但對主動脈容積度卻無影響。而在脈波反射現象方面，Ator對於波傳輸時間以及波反射係數分別有著15.4% 的增加 (P<0.05)，以及33.5% 的減低 (P<0.001)，顯示Ator能夠有效降低糖尿病所引起之左心室收縮負荷的增加，以改善糖尿病所導致之心室肥厚的現象，此結果可由左心室重量對體重的比值有顯著下降得到證實。 結論：給予STZ－糖尿病鼠低劑量的Ator，能夠在不影響總膽固醇的情況下，降低脂質氧化物丙二醛，並顯著地改善糖尿病所導致的主動脈硬化以及左心室肥厚的現象。 | zh_TW |
| dc.description.abstract | Background and purpose: Patients with diabetes mellitus have the characteristics of hyperglycemia and dyslipidemia, leading to an increase in oxidative stress and a decrease in nitric oxide (NO) bioavailability. These can cause endothelial dysfunction, which is an important process in the pathogenesis of cardiovascular diseases in diabetes. Statins, inhibitors of 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase, are often utilized in the prevention of cardiovascular diseases by their efficacy at lowering lipid levels. Statins may also reduce the incidence of cardiovascular events by their non-lipid or pleiotropic effects. It has been reported that low-dose therapy by atorvastatin (Ator), one of currently available statins, did not alter the lipid profile but led to a reduction in oxidative stress. The aim of the current study was to determine whether such a low-dose Ator could produce benefits on the mechanical properties of arterial system through its decrease of oxidative stress in streptozotocin (STZ)-induced diabetic rats.
Methods: Diabetes was induced in male Wistar rats at two monthes by a single tail vein injection of STZ 55 mg kg-1. After induction of hyperglycemia, the diabetic rats daily treated with Ator 10 mg kg-1 for six weeks by oral gavage were compared with the untreated age-matched diabetic controls. Pulsatile aortic pressure and flow signals were measured to describe the physical properties of the arterial system along with the pulse wave reflection phenomena. At the end of the experiment, blood and tissue samples were collected to obtain the plasma levels of free fatty acid (FFA), total cholesterol and the plasma and tissue levels of malondialdehyde/thiobarbituric acid reactive substances (MDA/TBARS). Results: In the absence of any significant changes in total cholesterol, the low dosage of Ator used in this study lowered the plasma levels of free fatty acid and the plasma and tissue levels of MDA/TBARS in diabetes. After exposure to Ator, the STZ-induced diabetic rats showed no significant changes in aortic pressure profile, basal heart rate, cardiac output and total peripheral resistance. Meanwhile, aortic characteristic impedance but not aortic compliance increased markedly in response to Ator therapy in the diabetic animals. As for wave reflection phenomena, Ator exhibited significant changes in both wave transit time by +15.4% (P<0.05) and wave reflection factor by -33.5% (P<0.001). These suggested that Ator may attenuate the diabetes-induced augmentation in systolic load imposed on the heart. The decline in systolic load by Ator treatment could be responsible for the prevention of the diabetes-related cardiac hypertrophy, as manifested by the diminished ratio of left ventricular weight to body weight. Conclusion: Our data suggest that low-lose Ator therapy may attenuate the diabetes-induced aortic stiffening and cardiac hypertrophy, possibility through its decrease of lipid oxidation-derived MDA/TBARS but not related to the total cholesterol-lowering effects of Ator in the STZ-diabetic rats. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-07T18:14:12Z (GMT). No. of bitstreams: 1 ntu-101-R99548030-1.pdf: 2310249 bytes, checksum: 99447148b216b732c55f9400c0a313d9 (MD5) Previous issue date: 2012 | en |
| dc.description.tableofcontents | 目錄......................................................ii
縮寫名詞對照表..............................................vi 中文摘要....................................................x Abstract.................................................xii 表次.....................................................xiv 圖次.....................................................xiv 文獻回顧....................................................1 一、 糖尿病..............................................1 1-1 糖尿病流行病學.......................................1 1-2 糖尿病簡介..........................................1 1-3 糖尿病分類..........................................2 1-4 糖尿病對血管的影響....................................3 1-4-1 氧化壓力的形成.......................................3 1-4-2 內皮細胞生理功能......................................5 1-4-3 內皮細胞功能異常......................................5 二、 Statins............................................7 2-1 Statins的簡介.......................................7 2-2 Statins的功能.......................................7 2-3 Statins的功能—降低血脂...............................8 2-4 Statins的功能-多效作用...............................9 2-4-1 降低氧化壓力........................................10 2-4-2 增加eNOS表現量.....................................11 2-4-3 發炎反應的抑制......................................11 2-5 Statins可能的副作用.................................12 三、 鏈佐菌素引發之糖尿病動物模式...........................13 四、 動脈物理性質之量化...................................14 4-1 主動脈輸入阻抗頻譜與左心室後負荷........................14 研究目的...................................................17 材料與方法.................................................18 一、 實驗動物製備........................................18 二、 實驗動物分組........................................18 三、 實驗儀器介紹........................................19 3-1 壓力感應器.........................................19 3-2 高傳真壓力感應器.....................................19 四、 實驗流程...........................................20 五、 左心室/體重比.......................................21 六、 資料轉換與分析方法...................................21 6-1 平均週期運算法則.....................................22 6-2 時序校正...........................................22 6-3 血行力學參數之計算與分析..............................23 6-3-1 主動脈輸入阻抗頻譜...................................23 6-3-2 主動脈容積度........................................25 6-3-3 前進波、反射波與波反射係數推算.........................26 6-3-4 波傳輸時間的推算.....................................27 七、 生化資料分析........................................27 7-1 游離脂肪酸的檢測.....................................27 7-2 總膽固醇的檢測......................................28 7-3 丙二醛/硫代巴比妥酸反應物質的檢測.......................28 八、 統計方法...........................................29 結果......................................................31 一、 基本資料...........................................31 二、 主動脈輸入阻抗頻譜...................................31 三、 穩態血行力學參數.....................................32 四、 脈態血行力學參數.....................................33 五、 生化物質...........................................33 討論......................................................35 一、 糖尿病及餵食Ator對心血管動脈物理特性之影響...............35 1-1 基本資料...........................................35 1-2 穩態參數部分........................................36 1-3 脈態參數部分........................................38 1-3-1 波傳輸時間與波反射係數................................38 1-3-2 主動脈特徵阻抗......................................39 1-3-3 主動脈容積度........................................40 二、 糖尿病及餵食Ator對生化物質之影響.......................41 結論......................................................43 實驗限制...................................................44 參考文獻...................................................52 | |
| dc.language.iso | zh-TW | |
| dc.title | Atorvastatin可改善streptozotocin所誘發糖尿病鼠之動脈硬化及心室肥厚 | zh_TW |
| dc.title | Atorvastatin attenuates arterial stiffness and cardiac hypertrophy in streptozotocin-induced diabetic rats | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 100-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 柯文哲,陳益祥 | |
| dc.subject.keyword | Atorvastatin,STZ誘發之糖尿病鼠,主動脈輸入阻抗頻譜分析,氧化壓力,總膽固醇,丙二醇, | zh_TW |
| dc.subject.keyword | Atorvastatin,STZ-induced diabetic rats,aortic input impedance analysis,oxidative stress,total cholesterol,MDA, | en |
| dc.relation.page | 69 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2012-06-04 | |
| dc.contributor.author-college | 工學院 | zh_TW |
| dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
| Appears in Collections: | 醫學工程學研究所 | |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| ntu-101-1.pdf Restricted Access | 2.26 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.